SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

GENEVA, SWITZERLAND / / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative ...

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues ...

The financing round was jointly led by new investor Regeneron Ventures and current investor Deerfield Management.

If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of ...

Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumorsNew candidate APVO455 targets Nectin-4+ cancers, joins miple ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

The global hypoparathyroidism treatment market is expected to experience significant growth from USD 785.7 million in 2025 to USD 1,152.9 million by 2035, reflecting a CAGR of 3.9% during the forecast ...

NurExone’s acceptance into the prestigious HTH Accelerator Program will support the Company’s expansion into the U.S. market following the establishment of Exo-top Inc. (“ Exo-TOP ”), the Company’s ...

Q4 2025 Earnings Call Transcript June 17, 2025 Beyond Air, Inc. beats earnings expectations. Reported EPS is $-0.09, ...